Gilead Shares Fall as Consensus EPS Estimate Slips
The stock lagged major indexes in its latest session as forecasts called for lower quarterly earnings and slightly higher revenue.
Gilead Sciences shares fell 1.21% to $149.45 in the latest trading session, underperforming the S&P 500, which lost 0.25%. The Dow fell 0.86%, while the Nasdaq rose 0.24%.
In the month before the session, Gilead shares had gained 0.91%. Over the same period, the Medical sector lost 1.01% and the S&P 500 fell 0.42%.
Zacks consensus estimates project quarterly earnings of $2.15 per share, down 12.96% from the same quarter last year. Revenue is forecast at $7.79 billion, up 0.3% year over year.
For the annual period, Zacks consensus estimates call for a loss of $0.48 per share and revenue of $30.74 billion. Those figures represent year-over-year changes of -105.89% and +4.4%, respectively.
The Zacks consensus EPS estimate has fallen 2.2% over the past 30 days, according to the report. Gilead’s upcoming earnings disclosure is the next event flagged in the article, which gives no date for the release.
This article was produced with the help of AI technology.
Source: Yahoo Finance
